A statement released today by Kepler Cheuvreux about Carl Zeiss Meditec (ETR:AFX) raises the target price to 38.00EUR
- Updated: February 11, 2017
Carl Zeiss Meditec (ETR:AFX) had its target bumped up to 38.00EUR by Kepler Cheuvreux in a report released Sunday February 12, 2017. The new target price suggests a potential upside of 0.02% from the company's last closing price.
Previously on 2/11/2017, Kepler Cheuvreux reported on Carl Zeiss Meditec (ETR:AFX) increased the target price from 0.00EUR to 38.00EUR. At the time, this indicated a possible upside of 0.02%.
Just yesterday Carl Zeiss Meditec (ETR:AFX) traded 0.00% even at 37.14EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last stock close price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the date range. Volume of trade held steady, with 0 shares of AFX changing hands on par with the typical 0
Recent Performance Chart
Carl Zeiss Meditec has with a one year low of 0.00EUR and a one year high of 0.00EUR and has a market capitalization of 0 EUR.
General Company Details For Carl Zeiss Meditec (ETR:AFX)
Carl Zeiss Meditec AG is a Germany-based medical technology and device company. It offers offers complete solutions to diagnose and treat ophtalmic diseases, visualization solutions for microsurgery and other technologies, such as intraoperative radiotherapy. The Company operates in two segments: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment comprises activities in the area of ophthalmology, such as intraocular lenses, surgical visualization solutions and medical laser and diagnostic systems. The Microsurgery segment includes activities of neuro, ear, nose and throat surgery, as well as the activities in the field of intraoperative radiation. The Company has various production sites in Europe, the United States and Asia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.